Fever after Zoledronic Acid Administration Is Due to Increase in TNF-α and IL-6

Journal of Interferon and Cytokine Research

Volumn 23, Issue 11, 2003, Pages 649-654

  Dicuonzo, Giordano ^a   Vincenzi, Bruno ^a   Santini, Daniele ^a   Avvisati, Giuseppe ^a   Rocci, Laura ^a   Battistoni, Fabrizio ^a   Gavasci, Michele ^a   Borzomati, Domenico ^a   Coppola, Roberto ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ETIDRONIC ACID; GAMMA INTERFERON; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INFUSION; EVALUATION; FEMALE; FEVER; HUMAN; LABORATORY; MALE; MALIGNANT NEOPLASTIC DISEASE; PARAMETER; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN FUNCTION; RECORDING; STANDARD; STATISTICAL SIGNIFICANCE; TIME;

ACUTE-PHASE REACTION; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BONE RESORPTION; CALCIUM; DIPHOSPHONATES; FEMALE; FEVER; HUMANS; IMIDAZOLES; INTERFERON TYPE II; INTERLEUKIN-6; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10744232515     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999003322558782     Document Type: Article

References (31)

1. MILLER, P.D., BONNICK, S.L., ROSEN, C.J., ALTMAN, R.D., AVIOLI, L.V., DEQUEKER, J., FELSENBERG, D., GENANT, H.K., GENNARI, C., HARPER, K.D., HODSMAN, A.B., KLEEREKOPER, M., MAUTALEN, C.A., McCLUNG, M.R., MEUNIER, P.J., NELSON, D.A., PEEL, N.F., RAISZ, L.G., RECKER, R.R., UTIAN, W.H., WASNICH, R.D., and WATTS, N.B. (1990). Intermittent cyclical etidronate treatment of post-menopausal osteoporosis. N. Engl. J. Med. 323, 73-79, 1990.
2. REID, I.R., KING, A.R., ALEXANDER, C.J., and IBBERTSON, H.K. (1988). Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)- 1,1-bisphosphonate (APD). Lancet 1, 143-146.
3. ROUX, C., GENNARI, C., FARRERONS, J., DEVOGELAER, J.P., MULDER, H., KRUSE, H.P., PICOT, C., TITEUX, L., REGINSTER, J.Y., and DOUGADOS, M. (1995). Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum. 38, 851-858.
4. BERENSON, J.R., LICHTENSTEIN, A., PORTER, L., DIMOPOULOS, M.A., BORDONI, R., GEORGE, S., LIPTON, A., KELLER, A., BALLESTER, O., KOVACS, M.J., BLACKLOCK, H.A., BELL, R., SIMEONE, J., REITSMA, D.J., HEFFERNAN, M., SEAMAN, J., and KNIGHT, R.D. (1996). Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. 334, 488-493.
5. HORTOBAGYI, G.N., THERIAULT, R.L., PORTER, L., BLAYNEY, D., LIPTON, A., SINOFF, C., WHEELER, H., SIMEONE, J.F., SEAMAN, J., and KNIGHT, R.D. (1996). Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335, 1785-1791.
6. SAAD, F., GLEASON, D.M., MURRAY, R., TCHEKMEDYIAN, S., VENNER, P., LACOMBE, L., CHIN, J.L., VINHOLES, J.J., GOAS, J.A., and CHEN, B. ZOLEDRONIC ACID PROSTATE CANCER STUDY GROUP. (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 94, 1458-1468.
7. FLEISCH, H. (1991). Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcemic and metastatic bone disease. Drug 42, 919-944.
8. GREEN, J.R., MÜLLER, K., and JAEGGI, K.A. (1994). Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. 9, 745-751.
9. MAJOR, P., LORTHOLARY, A., HON, J., ABDI, E., MILLS, G., MENSSEN, H.D., YUNUS, F., BELL, R., BODY, J., QUEBEFEHLING, E., and SEAMAN, J. (2001). Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. 19, 558-567.
10. BERENSON, J.R., VESCIO, R.A., ROSEN, L.S., VONTEICHERT, J.M., WOO, M., SWIFT, R., SAVAGE, A., GIVANT, E., HUPKES, M., HARVEY, H., and LIPTON, A. (2001). A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin. Cancer Res. 7, 478-485.
11. CHEER, S.M., and NOBLE, S. (2001). Zoledronic acid. Drugs 61, 799-805.
12. CHEN, T., BERENSON, J., VESCIO, R., SWIFT, R., GILCHICK, A., GOODIN, S., LORUSSO, P., MA, P., RAVERA, C., DECKERT, F., SCHRAN, H., SEAMAN, J., and SKERJANEC, A. (2000). Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol. 42, 1228-1236.
13. BAZZONI, F., and BEUTLER, B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334, 1717-1725.
14. DINARELLO, C.A. (2000). The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N. Engl. J. Med. 343, 732-734.
15. JOHNSON, M. (1996). Neoplastic fever. Palliat. Med. 10, 217-224.
16. BAUMANN, H., and GAULDIE, J. (1990). Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol. Biol. Med. 7, 147-159.
17. GANTER, U., ARCONE, R., TONIATTI, C., MORRONE, G., and CILIBERTO, G. (1989) Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J. 8, 3773-3779.
18. THIEBAUD, D., SAUTY, A., BURCKHARDT, P., LEUENBERGER, P., SITZLER, L., GREEN, J.R., KANDRA, A., ZIESCHANG, J., and IBARRA DE PALACIOS, P. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif. Tissue Int. 61, 386-392.
19. SAUTY, A., PECHERSTORFER, M., ZIMMER-ROTH, I., FIORONI, P., JUILLERAT, L., MARKERT, M., LUDWIG, H., LEUENBERGER, P., BURCKHARDT, P., and THIEBAUD, D. (1996). Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18, 133-139.
20. PENNANEN, N., LAPINJOKI, S., URTTI, A., and MONKKONEN, J. (1995). Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm. Res. 12, 916-922.
21. SCHWEITZER, D.H., OOSTENDORP-VAN DE RUIT, M., VAN DER PLUIJM, G., LOWIK, C.W., and PAPAPOULOS, S.E. (1995). Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J. Bone Miner. Res. 10, 956-962.
22. BURGER, E.H., VAN DER MEER, J.W., VAN DE GEVEL, J.S., GRIBNAU, J.C., THESINGH, G.W., and VAN FURTH, R. (1982). In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes. J. Exp. Med. 156, 1604-1614.
23. PIOLI, G., GIRASOLE, G., PEDRAZZONI, M., SANSONI, P., ERROI, A., DAVOLI, L., CIOTTI, G., MANTOVANI, A., and PASSERI, M. (1989). Spontaneous release of interleukin-1 (IL-1) from medullary mononuclear cells of pagetic subjects. Calcif. Tissue Int. 45, 257-259.
24. MONKKONEN, J., SIMILA, J., and ROGERS, M.J. (1998). Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sci. 62, PL95-102.
25. SANTINI, D., VINCENZI, B., AVVISATI, G., DICUONZO, G., BATTISTONI, F., GAVASCI, M., SALERNO, A., DENARO, V., and TONINI, G. (2002). Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin. Cancer Res. 8, 1080-1084.
26. KUNZMANN, V., BAUER, E., FEURLE, J., WEISSINGER, F., TONY, H.P., and WILHELM M. (2000). Stimulation of gamma/ delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96, 384-392.
27. GREEN, J.R. (2001). Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin. Oncol. 28, 4-10.
28. VINCENZI, B., SANTINI, D., ROCCI, L., and TONINI, G. (2003). Bisphosphonates: new antiangiogenic molecules in cancer treatment? Ann. Oncol. 14, 806-807.
29. Green, J.R. (2002). Preclinical pharmacology of zoledronic acid. Semin. Oncol. 29(Suppl. 21), 3-11.
30. BERENSON, J.R. (2002). Treatment of hypercalcemia of malignancy with bisphosphonates. Semin. Oncol. 29(Suppl. 21), 12-18.
31. MAJOR, P. (2002). The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist 7, 481-491.